Japan's 2026 pharmacy exemption for a specified high-control medical device

Executive summary

On 1 September 2026, Japan's Ministry of Health, Labour and Welfare issued notice 医薬機審発0901第1号, partially amending the administrative notice governing the handling of insulin syringes supplied by pharmacies. The notice adds starch-derived absorbable topical hemostatic material, デンプン由来吸収性局所止血材, to the list of specified insured medical materials that qualify for a defined pharmacy route without the pharmacy separately obtaining a license to sell highly controlled medical devices.

The development is operationally relevant for Japanese channel design, but it is narrow. The exemption applies only when the device is supplied on a physician's prescription under Japan's social-insurance laws and the pharmacy meets specified control requirements. It does not change the device's approval, certification, notification, reimbursement listing or product classification. Nor does it remove the highly controlled medical-device sales-license requirement for transactions outside the listed conditions.

The legal and administrative change

The MHLW notice is titled, in translation, "Partial amendment concerning the handling of insulin syringes supplied by pharmacies." Its operative structure extends an existing pharmacy-handling logic to a defined group of highly controlled medical devices that correspond to specified insured medical materials and, separately, highly controlled devices listed in the drug-price standard.

The official MHLW copy lists starch-derived absorbable topical hemostatic material in the annex of specified insured medical materials. The same notice provides that a qualifying pharmacy may rely on the relevant handling approach when supplying such a device under a physician's prescription and under the social-insurance laws, provided the pharmacy satisfies all specified requirements.

The fact that the measure is an administrative notice is important. It is not a new Act or Cabinet Order, and it should not be presented as a wholesale reform of Japan's medical-device distribution licensing system. Its effect is practical and channel-specific: it removes the need for a separate highly controlled medical-device sales license in the defined pharmacy-supply scenario.

Conditions attached to the exemption

The notice applies controls designed to preserve traceability, safe use and professional oversight. The pharmacy must confirm the patient's use status and use history, provide appropriate instruction on use and management based on the package insert or other accompanying information, make the required entries in dispensing and medication-history records, handle and store the device appropriately, and maintain staff-training arrangements.

These conditions are not administrative decoration. They are the operational safeguards that make the exemption narrower than ordinary commercial distribution. The pharmacy is not simply receiving a commercial privilege; it is assuming a controlled dispensing function linked to a prescription, a patient and an insured supply pathway.

The notice also makes the boundary explicit: where the listed conditions do not apply, a pharmacy intending to sell or provide a highly controlled medical device must obtain the required sales license.

Why the addition of a hemostatic material matters

The inclusion of starch-derived absorbable topical hemostatic material is commercially meaningful because it may open a defined pharmacy route for a product category traditionally associated with hospital or procedure-based distribution. That can affect channel economics, contracting, inventory placement, patient access and the responsibilities allocated between manufacturers, wholesalers and pharmacies.

The change should not, however, be mistaken for a determination that the material is newly approved or newly reimbursed. The notice's function is to amend the handling framework and the relevant annex. Market-access teams must still verify the identity of the product, its Japanese approval or certification status, its reimbursement treatment, the prescription pathway and the pharmacy's ability to meet the operational conditions.

A product family may contain several presentations, indications or legal classifications. A channel decision based only on a product name or broad material description could therefore be wrong. The relevant question is whether the exact device supplied falls within the listed insured-material category and is supplied in the manner contemplated by the notice.

Consequences for manufacturers and distributors

Manufacturers should update Japanese distribution maps to identify pharmacies that may use the exemption and distinguish them from distributors operating under the ordinary license regime. Contracts should allocate responsibility for verifying prescriptions, reimbursement status, recordkeeping, storage, training, instruction and escalation of complaints or adverse events.

The change also creates a documentation opportunity. A channel partner should be able to demonstrate why the exemption applies to a particular transaction. A controlled checklist could record product identity, prescription reference, insured-supply basis, patient-use verification, instruction provided, storage confirmation and the responsible personnel. The manufacturer or primary distributor should define how those records are retained and how information is made available during audits or investigations, subject to applicable Japanese privacy and record-retention requirements.

What the notice does not change

The notice does not itself amend the product's approval, certification or notification. It does not create a new clinical indication, change the reimbursement value, or replace the technical and quality obligations applicable to the device. It also does not establish a general pharmacy entitlement to handle every highly controlled medical device without a license.

This boundary is especially important for global organizations whose commercial teams may summarize the change as "Japan allows pharmacies to sell the hemostat." That shorthand is incomplete. The legally useful formulation is that Japan has created or confirmed a conditional pharmacy-supply route without a separate highly controlled medical-device sales license for the specified insured material when the prescription, social-insurance and pharmacy-control requirements are met.

Implementation risks

The largest near-term risk is overextension. A pharmacy, distributor or sales representative may infer that listing in the annex eliminates the need to verify the prescription or reimbursement pathway. Another risk is fragmentation: commercial teams may change channel arrangements without informing quality, complaint-handling or regulatory functions. A third risk is product ambiguity where several hemostatic products, presentations or legal categories are marketed under similar names.

A proportionate implementation should therefore include a Japanese-language procedure or controlled work instruction, role-based training, a transaction-level evidence checklist and an escalation route for uncertain cases. The organization should also audit whether the pharmacy can provide the required patient instructions and maintain the relevant records rather than assuming that an existing pharmaceutical dispensing process automatically covers the device-specific requirements.

Cross-border implications

The notice has no direct effect on EU MDR or IVDR obligations. It is a Japan-specific distribution and licensing measure. It should not be used as a reason to change EU importer, distributor, registration, vigilance or post-market surveillance controls. For global companies, the appropriate approach is to reuse governance principles, clear responsibilities, training, traceability and complaint escalation, while keeping the legal analysis jurisdiction-specific.

Conclusion

MHLW notice 医薬機審発0901第1号 is a valid and operative development for Japanese market access. Its practical effect is to make a defined pharmacy distribution route available for starch-derived absorbable topical hemostatic material included in the relevant insured-material annex, provided the supply is prescription-based, occurs under the social-insurance laws and the pharmacy satisfies the specified control requirements.

The change is therefore meaningful but not broad. Manufacturers and distributors should update channel strategies, qualify pharmacy partners and preserve traceability, while avoiding the inaccurate conclusion that Japan has abolished licensing requirements or changed the underlying approval and reimbursement status of the device.